Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm: Ana Stankovic

Fluidigm has appointed Ana Stankovic to its board of directors. Stankovic is currently managing partner at Koliada Consulting, a firm focused on biotech, medical devices, and in vitro diagnostics. Previously, she was senior vice president for worldwide regional medical affairs and global health at Becton Dickinson. She served in senior roles at BD for more than a decade, leading medical affairs and clincal operations for various BD units. Prior to this, Stankovic was an associate clinical professor in the Department of Pathology, Microbiology, and Immunology at Vanderbilt University School of Medicine. She also served for two years as a guest lecturer in the Department of Pathology at Harvard Medical School, and is a former chief resident in the Department of Pathology at the University of Alabama at Birmingham.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.